Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fulcrum Therapeutics Q3 EPS $(0.31) Misses $(0.29) Estimate; Cash $200.6M

Author: Benzinga Newsdesk | October 29, 2025 06:02am
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 3.13 percent increase over losses of $(0.32) per share from the same period last year.

Posted In: FULC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist